Please login to the form below

Not currently logged in
Email:
Password:

Achillion

This page shows the latest Achillion news and features for those working in and with pharma, biotech and healthcare.

J&J buys firm seeking hepatitis B cure

J&J buys firm seeking hepatitis B cure

J&J is also continuing to research new HCV therapies, and earlier this year paid up to $1.1bn for the rights to Achillion Pharmaceuticals' pipeline of drugs, headed by

Latest news

  • J&J signs $1bn deal with Achillion for hepatitis C therapies J&J signs $1bn deal with Achillion for hepatitis C therapies

    Will license three candidates from Achillion Pharma.  . Johnson &Johnson (J&J) has fleshed outs its portfolio of hepatitis C virus drugs, licensing three candidates from Achillion Pharma in a deal valued ... The agreement - which sits alongside a $225m

  • Gilead and Achillion see 100% success rate in hep C trial Gilead and Achillion see 100% success rate in hep C trial

    Gilead and Achillion have posted impressive clinical study results for a new all-oral combination hepatitis C treatment. . ... be an all-Achillion regimen, predicted to hit the US market by the end of the decade.

  • Hepatitis C therapies: dawn of a new age Hepatitis C therapies: dawn of a new age

    Achillion Pharmaceuticals has DAAs sovaprevir, neceprevir and ACH 3102 in the works, Idenix and Janssen are collaborating on samatasvir and TMC 647055, and phase 2 development of JNJ 56914845 (Janssen) is

  • FDA forces Achillion to delay hepatitis C programme FDA forces Achillion to delay hepatitis C programme

    Abnormal liver functions detected in some patients taking sovaprevir. Achillion's development of its hepatitis C treatment sovaprevir will be delayed after reports of abnormal liver functions in some patients caused ... trials. According to Achillion,

  • On the horizon

    The drug is in phase II development with Achillion, which is seeking a corporate partner to assist in the compound's clinical and commercial development for hepatitis B as a primary

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Managing value: Why early asset development and commercialisation are important Managing value: Why early asset development and commercialisation are important

    For example, Alnylam Pharmaceuticals, with its lead product in phase III, has a market capitalisation of $7.4bn, despite having no marketed products; or Achillion Pharmaceuticals with a market capitalisation of

  • Pharma deals in May 2015 Pharma deals in May 2015

    Clearly a very successful and creative partnership! Choosing to opt for partnership over an acquisition, J&J closed a multiple licence with Achillion to build on its hepatitis C portfolio. ... 1, 300. Achillion/ J&J. Licence. Joint development and

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics